An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: A1: Pyrotinib with nab-paclitaxel|DRUG: A2: nab-paclitaxel|DRUG: B1: everolimus with nab-paclitaxel|DRUG: B2: nab-paclitaxel|DRUG: C1: PD-1 with nab-paclitaxel and famitinib|DRUG: C2: nab-paclitaxel|DRUG: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|DRUG: D2: nab-paclitaxel, with maintenance of capecitabine|DRUG: E1: everolimus with nab-paclitaxel|DRUG: E2: nab-paclitaxel
Sponsor: Fudan University